eligibility_summary
Eligible: adults ≥18 (male or non‑pregnant/non‑lactating females) with newly diagnosed Ph+ or BCR‑ABL1+ ALL, no prior TKI/chemo, ECOG ≤2, survival ≥3 mo, labs: ALT/AST ≤5×ULN, bilirubin <2×ULN, CrCl >30 mL/min, SpO2 ≥92%, EF ≥40%. Exclude: active HBV ≥2000 IU/mL (lower allowed with antivirals), HCV/HIV/syphilis, uncontrolled infection, autoimmune (CNS), heart/vascular disease incl HTN, PAH, severe bleeding, other cancer, TG ≥5.6, pregnancy/lactation, major surgery <14d, noncompliance, unsafe
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: ThisCART19A—an allogeneic anti‑CD19 CAR‑T cell therapy that redirects donor T cells to CD19 on B‑lineage blasts, inducing T‑cell–mediated cytotoxicity, Olverembatinib (HQP1351)—a third‑generation small‑molecule BCR‑ABL tyrosine kinase inhibitor, active vs T315I, blocking ABL signaling and leukemic proliferation, Fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent) used for lymphodepletion to promote CAR‑T expansion. Targets/pathways: CD19+ B‑lymphoblasts, BCR‑ABL1 oncogenic signaling with downstream RAS/MAPK, PI3K/AKT, and STAT pathways in Philadelphia chromosome–positive ALL. Single‑arm trial in newly diagnosed Ph+ ALL.